Dihydroartemisinin is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs, is recommended as the first-line anti-malarial drug with low toxicity. Dihydroartemisinin possesses promising anticancer activities and induce cancer cell death through apoptotic pathways.

Bractoppin is a drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem (t)BRCT domain (IC50 = 0.074 μM), which selectively inhibits substrate binding with nanomolar potency in vitro.

Etidocaine is an amino acidamide that acts as a local anesthetic with fast onset and long-acting properties.